BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25698658)

  • 1. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection.
    Russo A; Falcone M; Fantoni M; Murri R; Masucci L; Carfagna P; Ghezzi MC; Posteraro B; Sanguinetti M; Venditti M
    Clin Microbiol Infect; 2015 May; 21(5):493.e1-4. PubMed ID: 25698658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and factors associated with candidaemia following Clostridium difficile infection in adults within metropolitan Atlanta, 2009-2013.
    Vallabhaneni S; Almendares O; Farley MM; Reno J; Smith ZT; Stein B; Magill SS; Smith RM; Cleveland AA; Lessa FC
    Epidemiol Infect; 2016 May; 144(7):1440-4. PubMed ID: 26608090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
    Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England.
    Wilcox MH; Shetty N; Fawley WN; Shemko M; Coen P; Birtles A; Cairns M; Curran MD; Dodgson KJ; Green SM; Hardy KJ; Hawkey PM; Magee JG; Sails AD; Wren MW
    Clin Infect Dis; 2012 Oct; 55(8):1056-63. PubMed ID: 22784871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of candidemia in patients with Clostridium difficile infection.
    Falcone M; Venditti M; Sanguinetti M; Posteraro B
    Expert Rev Anti Infect Ther; 2016 Jul; 14(7):679-85. PubMed ID: 27254270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study.
    Drabek J; Nyc O; Krutova M; Stovicek J; Matejkova J; Keil R
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():55. PubMed ID: 26698842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
    Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection.
    Bass SN; Bauer SR; Neuner EA; Lam SW
    J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting.
    Scardina T; Labuszewski L; Pacheco SM; Adams W; Schreckenberger P; Johnson S
    Infect Control Hosp Epidemiol; 2015 Mar; 36(3):280-6. PubMed ID: 25695169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-genome sequencing improves discrimination of relapse from reinfection and identifies transmission events among patients with recurrent Clostridium difficile infections.
    Mac Aogáin M; Moloney G; Kilkenny S; Kelleher M; Kelleghan M; Boyle B; Rogers TR
    J Hosp Infect; 2015 Jun; 90(2):108-16. PubMed ID: 25935700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ribotype on all-cause mortality following Clostridium difficile infection.
    Inns T; Gorton R; Berrington A; Sails A; Lamagni T; Collins J; Perry J; Hill K; Magee J; Gould K
    J Hosp Infect; 2013 Jul; 84(3):235-41. PubMed ID: 23759667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
    Lam SW; Bass SN; Neuner EA; Bauer SR
    Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates in the epidemiology and management of candidemia and
    Falcone M; Tiseo G; Venditti M; Menichetti F
    Expert Rev Anti Infect Ther; 2019 May; 17(5):375-382. PubMed ID: 30982376
    [No Abstract]   [Full Text] [Related]  

  • 15. A prospective study of community-associated Clostridium difficile infections: the role of antibiotics and co-infections.
    Taori SK; Wroe A; Hardie A; Gibb AP; Poxton IR
    J Infect; 2014 Aug; 69(2):134-44. PubMed ID: 24780765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
    Vitikainen K; Haapamäki J; Färkkilä M; Anttila VJ; Arkkila P
    Scand J Gastroenterol; 2018 Aug; 53(8):947-951. PubMed ID: 30041549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
    Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
    Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.
    Gómez S; Chaves F; Orellana MA
    Anaerobe; 2017 Dec; 48():147-151. PubMed ID: 28830842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection.
    Sethi AK; Al-Nassir WN; Nerandzic MM; Bobulsky GS; Donskey CJ
    Infect Control Hosp Epidemiol; 2010 Jan; 31(1):21-7. PubMed ID: 19929371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
    Pettit NN; DePestel DD; Fohl AL; Eyler R; Carver PL
    Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.